ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Allogene Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.30−0.01 (-0.76%)
Close on Oct 19, 2026
- Market cap
- $427.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
90.5%
313M of 345M shares
Institutional holders
209
32 new, 28 sold out
Net institutional buying
129M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $620.11K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Pfizer Inc. | 22,032,040 | 9.00% | 13D (active) amendment | Nov 6, 2025 |
| Fhmlsp, L.P. | 19,445,046 | 5.60% | 13G (passive) amendment | Jun 30, 2026 |
| State Street Corporation | 19,025,826 | 5.50% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 11,450,079 | 5.30% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALLO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 30,146,963 | 8.73% | $62.71M | +11,055,868 | 0.00% |
| Frazier Life Sciences Management, L.P. | 22,446,668 | 6.50% | $46.69M | +18,650,000 | 1.02% |
| Pfizer Inc | 22,032,040 | 6.38% | $46.93M | – | 27.55% |
| State Street Corp | 19,025,826 | 5.51% | $39.57M | +10,365,520 | 0.00% |
| Tpg Gp A, LLC | 18,716,306 | 5.42% | $38.93M | – | 0.78% |
| Sio Capital Management, LLC | 13,323,431 | 3.86% | $27.71M | New | 4.59% |
| Primecap Management Co/Ca/ | 13,123,440 | 3.80% | $27.30M | +4,743,600 | 0.02% |
| Vanguard Capital Management LLC | 12,166,636 | 3.52% | $25.31M | +5,245,286 | 0.00% |
| FMR LLC | 12,009,043 | 3.48% | $24.98M | +10,419,213 | 0.00% |
| Citadel Advisors LLC | 10,087,770 | 2.92% | $20.98M | +3,294,150 | 0.00% |
| Two Sigma Investments, LP | 7,784,348 | 2.25% | $16.19M | +2,408,892 | 0.01% |
| Geode Capital Management, LLC | 7,049,328 | 2.04% | $14.67M | +2,925,150 | 0.00% |
| Goldman Sachs Group Inc | 6,148,959 | 1.78% | $12.79M | +3,382,715 | 0.00% |
| GordonMD Global Investments LP | 5,298,000 | 1.53% | $11.02M | +3,868,000 | 5.33% |
| Marshall Wace, Llp | 5,095,408 | 1.47% | $10.60M | +1,647,424 | 0.01% |
| Patient Square Capital LP | 5,050,000 | 1.46% | $10.50M | +1,600,000 | 1.63% |
| abrdn plc | 5,001,752 | 1.45% | $10.40M | +3,539,533 | 0.01% |
| Millennium Management LLC | 4,843,889 | 1.40% | $10.08M | +1,521,836 | 0.00% |
| D. E. Shaw & Co., Inc. | 4,710,735 | 1.36% | $9.80M | +1,946,959 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 4,639,283 | 1.34% | $9.65K | −741,619 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 209 | 313M | 90.5% | 32 / 99 | 51 / 28 | 140M | 12M |
| Q1 2026 | 209 | 184M | 53.3% | 51 / 79 | 41 / 12 | 50M | 19M |
| Q4 2025 | 172 | 163M | 47.2% | 29 / 52 | 47 / 20 | 17M | 15M |
| Q3 2025 | 170 | 163M | 47.2% | 30 / 61 | 37 / 16 | 23M | 45M |
| Q2 2025 | 158 | 185M | 53.5% | 16 / 52 | 46 / 27 | 7M | 20M |
| Q1 2025 | 171 | 197M | 57.1% | 28 / 65 | 40 / 29 | 37M | 28M |
| Q4 2024 | 174 | 189M | 54.6% | 32 / 62 | 42 / 14 | 40M | 20M |
| Q3 2024 | 156 | 168M | 48.8% | 11 / 59 | 48 / 28 | 30M | 14M |
| Q2 2024 | 175 | 169M | 49.0% | 30 / 65 | 43 / 15 | 41M | 13M |
| Q1 2024 | 161 | 141M | 40.8% | 23 / 56 | 45 / 32 | 26M | 16M |
| Q4 2023 | 170 | 131M | 37.9% | 40 / 51 | 51 / 22 | 22M | 21M |
| Q3 2023 | 154 | 130M | 37.7% | 13 / 67 | 37 / 29 | 8M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALLO | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 12,142,998 | 3.51% | $25.26M | 0.24% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 9,546,893 | 2.76% | $20.72M | 0.39% | May 31, 2026 |
| Vanguard Capital Opportunity Fund | 9,388,170 | 2.72% | $19.53M | 0.06% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 8,666,591 | 2.51% | $18.03M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,916,407 | 2.00% | $14.39M | 0.02% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 3,475,270 | 1.01% | $6.53M | 0.09% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 3,444,101 | 1.00% | $7.16M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 3,223,886 | 0.93% | $6.71M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,909,372 | 0.84% | $5.47M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 2,479,776 | 0.72% | $5.16M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,803,716 | 0.52% | $3.75M | 0.04% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund | 1,798,280 | 0.52% | $3.38M | 0.14% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 1,442,118 | 0.42% | $3.13M | 0.06% | May 29, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1,438,234 | 0.42% | $2.99M | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,317,691 | 0.38% | $2.86M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David D. Chang | President and CEO, Director | 6,351,707 | 1.84% | Mar 18, 2026 |
| Earl Martin Douglas | SVP, General Counsel | 488,267 | 0.14% | Aug 25, 2026 |
| Zachary Roberts | President and CEO | 581,166 | 0.17% | Jul 6, 2026 |
| Annie Yoshiyama | SVP, Finance | 124,517 | 0.04% | Apr 23, 2026 |
| Benjamin Machinas Beneski | SVP, Chief Technical Officer | 195,338 | 0.06% | Apr 2, 2026 |
| Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | 1,252,795 | 0.36% | Feb 4, 2026 |
| Timothy L. Moore | Chief Technical Officer | 250,713 | 0.07% | Feb 5, 2025 |
| Owen N. Witte | Director | 292,832 | 0.08% | Jun 23, 2026 |
| Vicki L. Sato | Director | 162,575 | 0.05% | Jun 23, 2026 |
| Elizabeth A. Barrett | Director | – | – | Jun 23, 2026 |
| Stephen Mayo | Director | 25,328 | 0.01% | Jun 23, 2026 |
| Deborah M. Messemer | Director | 113,966 | 0.03% | Jun 23, 2026 |
| Franz B. Humer | Director | 307,507 | 0.09% | Jun 23, 2026 |
| Joshua A. Kazam | Director | 398,463 | 0.12% | Jun 23, 2026 |
| Arie Belldegrun | Director | 6,946,936 | 2.01% | Feb 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Earl Martin Douglas SVP, General Counsel | Aug 21, 2026 | Sale | −29,697 | $2.12 | $62.96K | 488,267 |
| Joshua A. Kazam Director | Jun 18, 2026 | Option exercise | +47,700 | – | – | 398,463 |
| Annie Yoshiyama SVP, Finance | Apr 21, 2026 | Sale | −9,586 | $2.31 | $22.14K | 124,517 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 31, 2026 | Sale | −2,867 | $2.50 | $7.17K | 195,338 |
| David D. Chang President and CEO, Director | Mar 16, 2026 | Sale | −47,763 | $2.47 | $117.97K | 5,150,599 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 16, 2026 | Sale | −4,835 | $2.47 | $11.94K | 198,205 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 2, 2026 | Sale | −7,132 | $2.60 | $18.54K | 203,040 |
| Annie Yoshiyama SVP, Finance | Feb 2, 2026 | Sale | −4,167 | $1.72 | $7.17K | 130,322 |
| David D. Chang President and CEO, Director | Feb 2, 2026 | Sale | −95,269 | $1.80 | $171.48K | 5,185,862 |
| Zachary Roberts EVP of R&D | Feb 2, 2026 | Sale | −35,700 | $1.77 | $63.19K | 581,166 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Feb 2, 2026 | Sale | −24,001 | $1.76 | $42.24K | 1,252,795 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Feb 2, 2026 | Sale | −7,549 | $1.73 | $13.06K | 210,172 |
| Earl Martin Douglas SVP, General Counsel | Feb 2, 2026 | Sale | −22,900 | $1.76 | $40.30K | 564,948 |
| Zachary Roberts EVP of R&D | Jan 21, 2026 | Sale | −26,269 | $1.56 | $40.98K | 616,866 |
| Joshua A. Kazam Director | Dec 18, 2025 | Option exercise | +47,700 | – | – | 350,763 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Nov 17, 2025 | Sale | −786 | $1.22 | $959 | 217,721 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Oct 21, 2025 | Sale | −36,744 | $1.26 | $46.30K | 1,276,796 |
| Deborah M. Messemer Director | Jun 10, 2025 | Sale(10b5-1 plan) | −36,885 | $1.42 | $52.38K | 107,431 |
| Annie Yoshiyama SVP, Finance | Apr 21, 2025 | Sale | −9,601 | $1.41 | $13.54K | 130,663 |
| David D. Chang President and CEO, Director | Mar 14, 2025 | Sale | −46,668 | $1.96 | $91.47K | 5,276,569 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 14, 2025 | Sale | −5,488 | $1.98 | $10.87K | 218,507 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 1, 2025 | Award | +31,755 | – | – | 223,995 |
| Deborah M. Messemer Director | Feb 18, 2025 | Sale(10b5-1 plan) | −13,313 | $2.43 | $32.35K | 144,316 |
| Zachary Roberts EVP of R&D | Feb 3, 2025 | Sale | −18,832 | $1.70 | $32.01K | 643,135 |
| Timothy L. Moore Chief Technical Officer | Feb 3, 2025 | Sale | −14,746 | $1.71 | $25.22K | 250,713 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Feb 3, 2025 | Sale | −4,361 | $1.73 | $7.54K | 1,301,540 |
| Earl Martin Douglas SVP, General Counsel | Feb 3, 2025 | Sale | −6,404 | $1.71 | $10.95K | 587,848 |
| David D. Chang President and CEO, Director | Feb 3, 2025 | Sale | −46,003 | $1.68 | $77.29K | 5,317,237 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Jan 24, 2025 | Award | +173,913 | – | – | 1,305,901 |
| David D. Chang President and CEO, Director | Jan 24, 2025 | Award | +552,174 | – | – | 5,363,240 |
| Zachary Roberts EVP of R&D | Jan 24, 2025 | Award | +173,913 | – | – | 661,967 |
| Earl Martin Douglas SVP, General Counsel | Jan 24, 2025 | Award | +144,928 | – | – | 594,252 |
| Arie Belldegrun Director | Jan 24, 2025 | Award | +369,957 | – | – | 2,236,816 |
| Annie Yoshiyama SVP, Finance | Jan 24, 2025 | Award | +36,232 | – | – | 137,990 |
| Zachary Roberts EVP of R&D | Jan 21, 2025 | Sale | −27,199 | $1.78 | $48.41K | 488,054 |
| Deborah M. Messemer Director | Dec 9, 2024 | Sale(10b5-1 plan) | −9,136 | $2.18 | $19.92K | 157,629 |
| Franz B. Humer Director | Dec 5, 2024 | Sale | −9,221 | $2.16 | $19.92K | 307,507 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Oct 21, 2024 | Tax withholding | −36,404 | $2.84 | $103.39K | 1,131,988 |
| Earl Martin Douglas SVP, General Counsel | Aug 21, 2024 | Tax withholding | −28,310 | $2.79 | $78.98K | 449,324 |
| Deborah M. Messemer Director | Jun 18, 2024 | Sale(10b5-1 plan) | −18,641 | $2.28 | $42.50K | 166,765 |
| Deborah M. Messemer Director | Jun 5, 2024 | Award | +122,950 | – | – | 185,406 |
| Franz B. Humer Director | Jun 5, 2024 | Award | +61,475 | – | – | 316,728 |
| Vicki L. Sato Director | Jun 5, 2024 | Award | +61,475 | – | – | 162,575 |
| Franz B. Humer Director | May 30, 2024 | Sale | −11,200 | $2.34 | $26.21K | 255,253 |
| David D. Chang President and CEO, Director | May 16, 2024 | Award | +344,828 | $2.90 | $1.00M | 4,810,106 |
| Arie Belldegrun Director | May 16, 2024 | Award | +344,828 | $2.90 | $1.00M | 539,867 |
| Arie Belldegrun Director | May 16, 2024 | Buy | +1,724,137 | $2.90 | $5.00M | 1,724,137 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | May 16, 2024 | Award | +344,828 | $2.90 | $1.00M | 1,164,418 |
| Timothy L. Moore Chief Technical Officer | Apr 22, 2024 | Tax withholding | −17,360 | $3.47 | $60.24K | 265,459 |
| David D. Chang President and CEO, Director | Mar 14, 2024 | Tax withholding | −53,393 | $4.33 | $231.19K | 4,465,278 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Jan 30, 2024 | Buy | +190 | $3.60 | $684 | 819,590 |
| Earl Martin Douglas SVP, General Counsel | Jan 25, 2024 | Award | +41,800 | – | – | 477,634 |
| Timothy L. Moore Chief Technical Officer | Jan 25, 2024 | Award | +96,600 | – | – | 282,819 |
| David D. Chang President and CEO, Director | Jan 25, 2024 | Award | +317,800 | – | – | 4,513,203 |
| Arie Belldegrun Director | Jan 25, 2024 | Award | +211,973 | – | – | 1,866,859 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Jan 25, 2024 | Award | +29,400 | – | – | 819,400 |
| Zachary Roberts EVP of R&D | Jan 25, 2024 | Award | +140,000 | – | – | 515,253 |
| Zachary Roberts EVP of R&D | Jan 22, 2024 | Tax withholding | −24,690 | $3.17 | $78.27K | 375,253 |
| Deborah M. Messemer Director | Dec 18, 2023 | Sale(10b5-1 plan) | −18,640 | $2.70 | $50.33K | 62,456 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Oct 16, 2023 | Award | +400,000 | – | – | 400,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Earl Martin Douglas Officer | Aug 21, 2026 | 29,697 | $62.96K | Aug 21, 2026 | Vesting of restricted stock unit award |
| Annie Yoshiyama Officer | Apr 21, 2026 | 9,586 | $22.10K | Apr 21, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Apr 1, 2026 | 2,867 | $7.17K | Apr 1, 2026 | Vesting of restricted stock unit award |
| David D. Chang Officer | Mar 16, 2026 | 47,763 | $117.83K | Mar 16, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Mar 16, 2026 | 4,835 | $11.93K | Mar 16, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Mar 2, 2026 | 7,132 | $18.54K | Mar 2, 2026 | Vesting of restricted stock unit award |
| M. Beneski Benjamin Officer | Feb 2, 2026 | 16,823 | $29.05K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Chang David Officer | Feb 2, 2026 | 243,976 | $438.52K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| J. Roberts Zachary Officer | Feb 2, 2026 | 35,700 | $63.35K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| T. Yoshiyama Annie Officer | Feb 2, 2026 | 4,167 | $7.18K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| M. Parker Geoffrey Officer | Feb 2, 2026 | 24,001 | $42.19K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Douglas Earl Officer | Feb 2, 2026 | 22,900 | $40.21K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Zachary Roberts Officer | Jan 21, 2026 | 26,269 | $40.93K | Jan 21, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Nov 17, 2025 | 786 | $959 | Nov 17, 2025 | Vesting of restricted stock unit award |
| Geoffrey M. Parker Officer | Oct 21, 2025 | 36,744 | $46.17K | Oct 21, 2025 | Vesting of restricted stock unit award |